JY
DCOY

Jeff Yass’s Decoy Therapeutics DCOY Stock Holding History

Jeff Yass’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21
Closed -$19.5K – 13242
2023
Q4 		$19.5K Buy
21
+11
+110% +$11K ﹤0.01% 11981
2023
Q3 		$9.07K Buy
10
+3
+43% +$3.98K ﹤0.01% 11730
2023
Q2 		$15.6K Buy
+7
New +$16K ﹤0.01% 11686
2021
Q1 		– Sell
-1
Closed -$30K – 12803
2020
Q4 		$30K Buy
+1
New +$29.3K ﹤0.01% 10844
2019
Q2 		– Hold
0
– -$17K – 10780
2019
Q1 		– Hold
0
– – – 8609
2018
Q4 		– Hold
0
– – – 8437
2018
Q2 		– Hold
0
– -$93K – 10340
2018
Q1 		– Hold
0
– – – 8730
2017
Q4 		– Hold
0
– – – 8900
2017
Q3 		– Hold
0
– -$49K – 9556
2017
Q2 		– Hold
0
– – – 8894
2017
Q1 		– Hold
0
– -$128K – 9865
2016
Q4 		– Hold
0
– – – 8955
2015
Q2 		– Hold
0
– -$267K – 10430
2015
Q1 		– Hold
0
– – – 8183

Other funds holding DCOY

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's DCOY Position: Q1 2024 in Review

Jeff Yass sold out of Decoy Therapeutics (DCOY) in Q1 2024, closing a stake of 21 shares — an estimated $19.5K sold.

Jeff Yass first reported a position in DCOY in Q4 2020 and held it in 4 quarters. The position peaked at $30K in Q4 2020. 7 funds tracked by Wall St. Rank hold DCOY as of Q1 2024.

  • Jeff Yass reported no remaining Decoy Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Jeff Yass sold 21 Decoy Therapeutics shares in Q1 2024, an estimated $19.5K.
  • Jeff Yass first reported a position in Decoy Therapeutics in Q4 2020 and held it in 4 quarters.
  • Jeff Yass's Decoy Therapeutics position peaked at $30K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.